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Abstract
Background: Glutathione (GSH), a major intracellular antioxidant, plays a role in NMDA receptor-mediated neurotrans-
mission, which is involved in the pathophysiology of schizophrenia. In the present study, we aimed to investigate whether
GSH levels are altered in the posterior medial frontal cortex of schizophrenic patients. Furthermore, we examined
correlations between GSH levels and clinical variables in patients.
Methods and Findings: Twenty schizophrenia patients and 16 age- and gender-matched normal controls were enrolled to
examine the levels of GSH in the posterior medial frontal cortex by using 3T SIGNA EXCITE
1H-MRS with the spectral editing
technique, MEGA-PRESS. Clinical variables of patients were assessed by the Global Assessment of Functioning (GAF), Scale
for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Drug-Induced Extra-Pyramidal
Symptoms Scale (DIEPSS), and five cognitive performance tests (Word Fluency Test, Stroop Test, Trail Making Test,
Wisconsin Card Sorting Test and Digit Span Distractibility Test). Levels of GSH in the posterior medial frontal cortex of
schizophrenic patients were not different from those of normal controls. However, we found a significant negative
correlation between GSH levels and the severity of negative symptoms (SANS total score and negative symptom subscore
on BPRS) in patients. There were no correlations between brain GSH levels and scores on any cognitive performance test
except Trail Making Test part A.
Conclusion: These results suggest that GSH levels in the posterior medial frontal cortex may be related to negative
symptoms in schizophrenic patients. Therefore, agents that increase GSH levels in the brain could be potential therapeutic
drugs for negative symptoms in schizophrenia.
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Introduction
Accumulating evidence suggests that oxidative stress associated
with impaired metabolism of the antioxidant glutathione (GSH)
plays a key role in the pathogenesis of schizophrenia [1,2]. First,
activity of glutathione peroxidase (GSH-Px), a key antioxidant
enzyme, was found to be decreased in red blood cells [3,4] and
plasma [5] of some, but not all schizophrenic patients [6,7].
Furthermore, plasma GSH-Px levels were significantly and
positively correlated with psychosis rating scores in schizophrenic
patients [8]. Second, it has been reported that the activity of
glutamate cysteine ligase (GCL), the rate-limiting enzyme for GSH
synthesis, as well as expression of the catalytic GCL subunit
(GCLL) protein in cultured skin fibroblasts from schizophrenic
patients were significantly decreased compared to those in
comparison subjects, and that decreased GCL activity was
correlated with decreased GCLL protein expression [9]. Third,
Do et al. [10] reported that levels of GSH in the cerebrospinal
fluid of drug-free patients of schizophrenia were significantly
decreased compared to those in normal comparisons. Further-
more, a study using postmortem brain samples demonstrated
decreased levels of GSH, oxidized GSH (GSSG), GSH-Px, and
GSH reductase in the caudate region of brains from schizophrenic
patients, suggesting impaired GSH metabolism in schizophrenic
brains [11]. Moreover, a 1.5T
1H-magnetic resonance spectros-
copy (MRS) study with double quantum coherence technique
demonstrated significant reduction (52 %) in GSH levels in the
medial frontal cortex of schizophrenic patients compared to
comparisons [10]. However, Terpstra et al. [12] reported that
levels of GSH in the anterior cingulated cortex, measured by 4T
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Solved Spectroscopy) sequence, did not differ in schizophrenic
patients and comparisons. Fourth, several genes involved in GSH
metabolism have been shown as potential candidate genes for
schizophrenia. Association of the glutathione-S-transferase (GST)
M1 gene was shown in schizophrenic subgroups in Japanese [13]
and Korean populations [14]. Recently, Tosic et al. [15] reported
that the levels of mRNA for GCLM and glutathione synthetase,
which are responsible for GSH synthesis, were significantly
decreased in the fibroblasts of schizophrenic patients in a Swiss
population. Subsequently, they reported the GCLM gene as a
susceptibility gene for schizophrenia in Swiss and Danish
populations [9,15]. Taken together, these findings provide genetic
and functional evidence that an impaired capacity to synthesize
GSH under conditions of oxidative stress is a vulnerability factor
for schizophrenia.
GSH plays a major role in the modulation of redox-sensitive
sites on the N-methyl-D-aspartate (NMDA) receptors [16–18],
which are implicated in the pathophysiology of schizophrenia [19–
23]. Considering the NMDA receptor hypofunction hypothesis for
schizophrenia [19–23], it is of great interest to study whether levels
of GSH are altered in the brains of schizophrenic patients. In the
present study, we aimed to investigate whether GSH levels are
altered in the posterior medial frontal cortex of schizophrenic
patients. Furthermore, we examined the correlations between
GSH levels and clinical features including the severity of clinical
symptoms (positive symptoms, negative symptoms and cognitive
deficits). In addition, we performed genetic analysis for the genes
involved in GSH metabolism: namely, GCLM, glutathione
peroxidase 1 (GPX1), and several classes (GSTM1, GSTO1,
GSTP1, GSTT1 and GSTT2) of glutathione-S-transferase
(GST).
Materials and Methods
Subjects
This research was performed under approval of the ethics
committee of Chiba University Graduate School of Medicine and
National Institute of Radiological Science. The experiments were
thoroughly explained to the subjects, and written informed consent
was obtained from all. Twenty schizophrenic patients and 16 age-
and gender- matched normal controls with no past history of
psychotic disorders or drug dependence were enrolled in the study.
Characteristics of subjects are shown in Table 1. Due to a few
highly educated comparisons, the extent of education and
estimated IQ were significantly different between the two groups,
but the estimated IQ of all patients was within the normal range.
All patients were outpatients meeting the DSM-IV criteria for
schizophrenia [24] and having no other psychiatric disorders. All
patients were taking second-generation neuroleptics: i.e., risperi-
done (2–12 mg/day, n=9), olanzapine (5–20 mg/day, n=5),
aripirprazole (6–12 mg/day, n=4), quetiapine (500 mg/day,
n=1) or perospirone (48 mg/day, n=1), with no change in their
medication for the past month. Of the patients, twelve were
diagnosed as residual type and eight were as paranoid type.
1H-MRS measurement and data analysis
Alldatawereacquiredusing the3T SIGNAEXCITE(GE)witha
standard quadrature coil. GSH spectra were acquired by the
MEGA-PRESS sequence [25]. A GSH peak at chemical shift
2.95 ppm originating from cysteinyl b-CH2 was observed by editing
pulse at 4.95 ppm a-CH resonance line J-coupled to the observed
spins. Acquisition parameters for the measurement were as follows:
echo time (TE)=94 ms, repetition time (TR)=1500 ms, number of
excitations (NEX)=512, band width 2.5 kHz, data point 4096. TE
and TR were set experimentally as optimum for our system after
confirmingthe GSH signalchanges to be withina certain range (TE:
62–101 ms, TR: 1077 ms–12000 ms) with both phantom solutions
and human subjects. The short TR enabled us to increase NEX and
obtain a satisfying signal/noise (S/N) ratio in the human brains. For
the quantification of GSH, we prepared eight phantom solutions
containing different concentration of GSH (0.3–30.0 mM) with N-
acetyl aspartate (NAA, 10 mM) and creatine (8 mM) to get the
reference spectra. During the phantom data acquisition, the
solutions were kept at 3760.6uC.
For the acquisition of human spectra, an 18.6-ml
(28630622 mm) volume of interest (VOI) was placed on the
posterior medial frontal cortex under the guidance of T2-weighed
images (Figure 1A). The posterior medial frontal cortex was
selected since reduction in the GSH levels in this region of
schizophrenic patients has been reported previously [10]. To
minimize variation in the positioning of the head, subjects were
positioned by the same investigator. The overall examination time
was 1 hour or less.
For all data acquisition, high-order shim followed by automatic
local shim adjustment was used and repeated until the half linewidth
was accomplished under 3 Hz(phantom) or 8 Hz (human). The raw
data of both phantom solutions and human subjects were processed
on GE analysis software (GE Medical Systems, Milwaukee, WI).
Fourier transform was done with an exponential weighting function
of 2 Hz. The area of the GSH signal was measured on Image J
(http://rsb.info.nih.gov/ij/) software.
Table 1. Characteristics and clinical variables of subjects
enrolled in this study
Variable Controls (n=16)
Schizophrenia
(n=20) P values
Sex, Male/Female 12/4 12/8 0.481
a)
Age (year) 30.067.2 (21–41) 30.765.8 (20–39) 0.581
b)
Education (year) 15.262.9 (12–21) 13.561.7 (12–16) 0.04
b)
Estimated IQ
*1 107.4617.3 (90–128) 98.6610.9 (80–114) 0.03
b)
age at onset of
illness (year)
23.665.5 (11–31)
Duration of illness
(year)
7.3065.2 (1–21)
GAF scale 51.5611.5 (29–71)
Amount of
medication
*2
283.16216(80–667)
BPRS score 26.268.6 (13–43)
BPRS positive score 12.265.7 (4–24)
BPRS negative score 6.162.9 (2–12)
SANS score 76.9612.9 (60–103)
DIEPSS score 0.4160.15 (0.11–0.78)
GSH (mM) 0.92860.24 (0.608–
1.465)
0.80860.26 (0.432–
1.250)
0.166
b)
All values are shown as mean6SD (range).
a)Chi-squire test,
b)Student t-test.
*1: Short form version of Wechsler Adult Intelligence Scale, Revised (WAIS-R)
*2: Chlorpromazine equivalent (mg)
GAF: Global Assessment of Functioning, BPRS: Brief Psychiatric Rating Scale,
SANS: Scale for the Assessment of Negative Symptoms, DIEPSS: Drug Induced
Extra-Pyramidal Symptoms Scale
doi:10.1371/journal.pone.0001944.t001
Glutathione and Schizophrenia
PLoS ONE | www.plosone.org 2 April 2008 | Volume 3 | Issue 4 | e1944Evaluation of clinical variables
The Scale for the Assessment of Negative Symptoms (SANS)
and Brief Psychiatry Rating Scale (BPRS) were used to evaluate
the severity of negative symptoms and psychotic symptoms
(positive and negative symptoms), respectively. The Drug-Induced
Extrapyramidal Symptoms Scale (DIEPSS) was used to evaluate
and exclude the effects of drug-induced extrapyramidal symptoms
which could affect the severity of symptoms in schizophrenic
patients. Functional disability was assessed using the Global
Assessment of Functioning (GAF) scale.
Cognitive function tests
Several cognitive function tests were used. In the Word Fluency
Task (letter, category), subjects were given an initial letter (letter
fluency task) or a certain category (category fluency task) as a cue
[26]. Both tasks consisted of three trials, and the number of words
produced in one minute for each trial was recorded for evaluation.
In the Stroop Test, a list of twenty four colored dots (D), a baseline
test, and 24 colored words incongruent with the color (C) were
used. The difference between the reaction time (C-D) was assessed
[27]. In the Wisconsin Card Sorting Test (WCST), subjects were
instructed to sort cards according to a rule (color, shape, or
number). The numbers of achieved categories and perseverative
errors were assessed [28]. In the Trail-Making Test part (TMT) A,
subjects drew lines as quickly as possible to connect 25
consecutively numbered circles. In the TMT part B, subjects
connected 25 consecutively numbered and lettered circles by
alternating between the two sequences. The time taken to
complete each part of the test was recorded in seconds [29]. In
the Digit Span Distractibility Test (DSDT), subjects were asked to
remember a tape-recorded string of digits read by a female voice
while ignoring the digits read by a male voice (distracter) [30].The
percentages of digits correctly recalled in conditions with and
without distracters were assessed separately.
Figure 1. Proton MRS of GSH. (A): T2-weighed magnetic resonance imaging of the targeted region. The blue boxes show the voxel size (28 x 22 x
30 mm) in the posterior medial frontal cortex of a human brain. (B): representative data of reference phantom spectra of GSH (0.5, 1.0, 3.0 mM). Note
that the GSH signal increases according to the phantom concentration. (C): Quantification of GSH. Plots showing a linear correlation (r2=0.994)
between the GSH signal area at 2.95 ppm and the concentration of GSH. (D): Representative data of GSH signals of the posterior medial frontal cortex
of a human subject. The GSH level was calculated as 0.735 mM by applying the linear concentration curve on (C).
doi:10.1371/journal.pone.0001944.g001
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Genetic analysis for the genes involved in GSH metabolism-
GCLM, glutathione peroxidase 1 (GPX1), and several classes of
glutathione-S-transferase (GSTM1, GSTO1, GSTP1, GSTT1 and
GSTT2)-as performed by the methods described previously
[15,31–33].
Statistical analysis
All calculations were performed with SPSS software (SPSS
version 12.0J, Tokyo, Japan). Student’s t-test (unpaired) was
employed for the comparison of GSH levels between schizo-
phrenic patients and normal control subjects and of the scores of
the cognitive function tests between the two groups. For the
genotyping results, the differences between patients and controls
were evaluated by Fisher’s exact test. Pearson’s correlation
coefficients were examined to identify any correlations of GSH
levels with the clinical severity (BPRS, SANS, and DIEPSS) of
schizophrenic patients and with the scores of cognitive function
tests of all subjects. A value of p,0.05 was used as the standard for
statistical significance in all analyses.
Results
GSH concentration between schizophrenic patients and
healthy comparisons
We used eight phantom solutions of different GSH concentra-
tions (0.3–30 mM) to acquire reference spectra for quantification.
As shown in Figure 1B, acquired GSH phantom spectra clearly
increased their areas at chemical shift 2.95 ppm in a concentra-
tion-dependent manner. In Figure 1C, plots show a linear
correlation (r
2=0.994) between the GSH signal area and the GSH
concentration. The areas of GSH spectra acquired from human
subjects in vivo were applied to the linear concentration curve for
quantification (Figure 1D). As shown in Table 1, GSH
concentration (0.80860.26 mM (mean6SD)) in the posterior
medial frontal cortex of schizophrenic patients (n=20) did not
differ (t=1.416, df=34, p=0.166) from that (0.92860.24 mM
(mean6SD)) of age- and gender-matched normal healthy controls
(n=16)(Table 1). Furthermore, there were no correlations
between GSH levels and clinical variables (age, education,
estimated IQ, age at onset of illness, duration of illness, GAF,
and amount of medication) in the subjects.
Correlation between GSH concentration and clinical
variables
We examined the correlation between GSH level and the
severity of clinical symptoms (scores of SANS, BPRS and DIEPSS)
in the schizophrenic patients (n=20). Interestingly, there was a
significant negative correlation (r=20.68, p,0.001) between
GSH level and SANS total score in schizophrenic patients
(Figure 2). Of five subscale-symptom groups in SANS, significant
negative correlations with GSH level were detected in four
subscales (S1: affective flattering-blunting (r=20.57, p=0.009),
S2: alogia (r=20.67, p=0.001), S3: avolition-apathy (r=20.52,
p=0.02), S4: anhedonia-asociality (r=20.62, p=0.004)), but not
in attention impairment (r=20.27, p=0.252). Furthermore, we
also found a significant correlation (r=20.60, p=0.005) between
GSH levels and the negative symptom subscore on BPRS.
However, there were no significant correlations between GSH
level and BPRS total score (r=20.41, p=0.076), BPRS positive
symptom score (r=20.43, p=0.059) and DIEPSS score
(r=20.32, p=0.167). Because these correlations might have
been affected by medication, we controlled for the doses of
antipsychotics using partial correlation coefficients. Even when the
administered antipsychotics (chlorpromazine equivalents) were
adjusted for using partial correlation coefficients, the relationships
between GSH level and SANS score (partial correlation
coefficient=20.60, p=0.007) or BPRS negative score (partial
correlation coefficient=20.52, p=0.02) remained significant.
Correlation between GSH concentration and cognitive
functions
As shown in Table 2, significant differences were observed
between schizophrenia patients and normal controls in all
cognitive function tests: Word Fluency (letters: t=4.67, df=34,
p,0.001; category: t=3.57, df=34, p,0.01), Stroop Task
(t=23.47, df=34, p,0.01), WCST (category: t=3.95, df=34,
p,0.001; perseverative error : t=24.61, df=34, p,0.001), Trail
Making Test (TMT-A: t=23.21, df=34, p,0.001; TMT-B:
t=23.43, df=34, p,0.01; TMT-B-A; t=22.17, df=34,
p=0.03), and DSDT (without distracter: t=1.35, df=34,
p=0.18; with distracter; t=3.23, df=34, p,0.01).
Then, we examined the correlations between GSH levels and
the scores of cognitive function tests. We found a significant
negative correlation (r=20.36, p=0.03) between GSH level and
TMT-A scores in all subjects (n=36)(Table 2). There were no
correlations between GSH levels and the scores of other cognitive
function tests (Table 2).
Correlations between GSH concentration and the
genotypes of enzymes related with GSH metabolism
There was a significantly (p=0.017) different genotype
distribution for the GSTT2 gene between schizophrenic patients
and healthy controls. No different distribution was observed in
other genes (Table S1). Then, we investigated whether or not
these genotypes affected GSH levels in the posterior medial frontal
Figure 2. Correlation between GSH levels and the severity of negative
symptoms in schizophrenia. There was a significant negative correlation
(r=2068, p,0.001) between GSH levels and SANS total scores of
schizophrenic patients (n=20).
doi:10.1371/journal.pone.0001944.g002
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relevant to those genotypes. However, we found a difference in
GSH levels between patients (n=15) and normal controls (n=5)
in subjects with the G/G genotype of the GSTT2 (Met139Ile)
gene, although the difference only showed a trend toward
statistical significance (p=0.058) (Figure S1). We also found a
difference in GSH levels between patients (n=13) and normal
controls (n=11) in subjects with the C/C genotype of the GCLM
(ss60297536) gene; again, the differences only showed a trend
toward statistical significance (p=0.099) (Figure S1).
Discussion
The major finding of this study was that GSH levels in the
posterior medial frontal cortex of schizophrenic patients were
significantly correlated with the severity of their negative
symptoms. To the best of our knowledge, this is the first report
demonstrating the negative correlation between brain levels of
GSH and the severity of negative symptoms in schizophrenia.
The measurement of brain GSH levels by
1H-MRS has been
elusive up until now because GSH exists at a relatively low
concentration and the cysteinyl b-CH2 signal of GSH at 2.95ppm
overlaps with other resonances such as those of aspartate, c-
aminobutylic acid (GABA), and especially creatine, with its high
concentration in human brain. The MEGA-PRESS sequence is
able to highlight the GSH signal by adding two editing pulses with
a normal PRESS sequence. Sufficient GSH signal was obtained by
setting an optimum condition with repeated preliminary measure-
ments using both phantom solutions and human subjects, and the
shorter TR than in previous studies [12,25,34] enabled us to
increase the number of scans within the short examination time.
In this study, we found no alteration in GSH concentrations in
the brains of schizophrenic patients, which was consistent with a
previous report using the MEGA-PRESS sequence [12], but not a
previous report using a double quantum coherence filter technique
[10]. The reasons underlying this discrepancy are currently
unclear. One possibility may be due to the difference of technique
(MEGA-PRESS sequence vs. a double quantum coherence filter)
for GSH measurement. Another possibility may be due to
medication. The patients enrolled in the study of Do et al. [10]
were first-episode patients whereas those in the present study and
that of Terpstra et al. [12] were medicated. However, in this study,
we found no effect of medication on GSH levels in schizophrenic
patients. Therefore, it is unlikely that medication contributes to
this discrepancy, although further study is necessary.
The present finding suggests that increasing the brain levels of
GSH should be considered a potential therapeutic approach for
negative symptoms in schizophrenia. It is well known that oral
administration of GSH does not result in its effective increase in
the brain because of its poor penetration through the blood-brain
barrier, indicating that GSH is not a suitable agent for treating
neuropsychiatric diseases such as schizophrenia. The antioxidant
N-acetyl-L-cysteine (NAC) has been widely used as a donor of
cysteine, the limiting precursor in the synthesis of GSH, and NAC
has a good penetration through the blood-brain barrier. Recently,
Lavoie et al. [35] reported that treatment of schizophrenic patients
with NAC significantly improved impaired mismatch negativity,
which is an auditory evoked potential component related to
NMDA receptor function [36]. Furthermore, a multi-center
double-blinded trial of NAC showed improvement of negative
symptoms on the Positive and Negative Symptoms Scale after
6 months of treatment with NAC ([36], Berk et al, unpublished
work). Interestingly, it has been reported that GSH-deficient mice
showed enhanced dopamine neurotransmission, altered serotonin
function, and augmented locomotor responses to low doses of the
NMDA receptor antagonist phencyclidine, suggesting that the
GSH deficiency produced alterations in monoaminergic function
and behavior in mice relevant to schizophrenia [37]. Moreover,
we reported that NAC could attenuate behavioral changes and
neurotoxicity in rodents and non-human primates after repeated
administration of the psychostimulant methamphetamine [38,39].
Taken together, the findings suggest that NAC has potential as a
therapeutic drug for negative symptoms in schizophrenia.
In this study, we found a weak negative correlation between
GSH levels in the posterior medial frontal cortex and TMT-A
scores. There was also a positive correlation (r=0.47, p=0.024)
between TMT-A scores and SANS total scores in schizophrenic
patients. The posterior medial frontal cortex can be divided
functionally into two parts: an upper half including Brodman areas
8 and 9 and a lower half including part of the anterior cingulate
cortex, Brodman areas 24 and 32 [40]. Both parts are shown to
play a role in self monitoring and control of action demanded in
the context of social cognitive processes [40]. The relation between
GSH level and cognitive symptoms might be assessed in more
detail by setting smaller and more specific VOI in the brain,
although it is currently difficult to get sufficient GSH signal with
smaller VOI. Nonetheless, it seems that GSH levels in the
posterior medial frontal cortex may be associated with cognitive
impairment as well as negative symptoms in schizophrenia.
Therefore, GSH levels in the posterior medial frontal cortex
may be a predictive biological factor for the severity of cognitive
impairment and negative symptoms in schizophrenia.
In this study, GSH levels were not affected by the genotypes of
several genes related to GSH metabolism. The genotype distribution
of GSTT2 was significantly (p=0.017) different between patients
(n=20) and normal controls (n=16), but this was considered to be a
type I error due to the small sample size, as our study using a larger
sample size (over 200 of both groups) revealed no significant
difference (Matsuzawa et al, submitted). Interestingly, we found that
brain GSH levels in patients with the C/C genotype of the GCLM
Table 2. Performance on cognitive function tests and their
correlations with GSH level
Cognitive function
test mean scores6SD
Coefficients
with GSH
level (r)
a)
Control subjects
(n=16)
Schizophrenia
(n=20)
Word Fluency (letter) 41.368.8 28.467.8
*** 0.15
Word Fluency (category) 48.968.4 39.866.9
** 0.21
Stroop test (C-D, sec) 5.863.9 12.166.4
** 20.05
WCST (category) 5.161.9 2.761.8
** 0.01
WCST (perserverative
error)
2.162.5 11.568.4
*** 20.23
TMT-A (sec) 21.866.7 32.068.4
** 20.36*
TMT-B (sec) 48.4618.2 80.5632.1
** 20.14
TMT B-A (sec) 26.6613.5 53.6651.3
* 0.06
DSDT (without distractor) 87.9612.8 80.3620.8 0.18
DSDT (with distractor) 93.067.2 74.4622.1
** 0.31
*P ,0.05, **P ,0.01, ***P ,0.0001 (vs.Control)
a)Pearson’s coefficients between GSH level in all subjects (n=36).
*P ,0.05
WCST : Wisconsin Card Sorting Test, TMT : Trail Making Test, DSDT : Digit Span
Distractibility Test
doi:10.1371/journal.pone.0001944.t002
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genotype of the GCLM (ss60297536) gene although the differences
only showed a trend toward statistical significance (p=0.099).
Further study using a large sample will be necessary to study the
relationship between GCLM gene polymorphism and GSH levels in
schizophrenic patients.
In conclusion, the present study suggests a negative correlation
between GSH levels in the posterior medial frontal cortex and the
severity of negative symptoms in schizophrenia. Therefore, agents
(e.g., NAC) that can increase brain GSH levels should be considered
potential therapeutic drugs for negative symptoms in schizophrenia.
Supporting Information
Figure S1 GSH levels and the relevance with polymorphisms of
GCLM and GSTT2 gene. The plots show GSH levels of controls
and patients with each genotype of GCLM-588 (left) and GSTT2
(right). The bars represent mean GSH level 6 standard deviation
(mM).
Found at: doi:10.1371/journal.pone.0001944.s001 (0.20 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0001944.s002 (0.05 MB
DOC)
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